News Sharing
For sharing news, please enter the email address of you and the receiver, then press SEND button.*Mandatory Fields
Receiver*
Enter email addresses, separated by semicolon (;). E.g. a@a.com;b@b.com
Your email address*
 Content Sharing
創勝集團(06628.HK)：ozekibart中期研究數據積極 評估大中華區計劃
創勝集團-B(06628.HK)公布，合作夥伴Inhibrx Biosciences(INBX.US)近期報告其評估ozekibart (INBRX-109)聯合FOLFIRI用於局部晚期或轉移性、不可切除結直腸癌(CRC)患者的1/2期研究的積極更新中期數據。Inhibrx亦宣布已於4月向FDA提交ozekibart用於常規軟骨肉瘤的生物製品許可申請。根據...
Reset
Send
The window will close in 5 seconds
創勝集團(06628.HK)：ozekibart中期研究數據積極 評估大中華區計劃
Close
Recommend
3
Positive
2
Negative
0
 
SHORT SELL
 
STOCK INFO
aacat by AASTOCKS
Open a new trading account to get 1 Intel/Selected Gold ETF share!

創勝集團-B(06628.HK)  0.000 (0.000%)   公布，合作夥伴Inhibrx Biosciences(INBX.US)      近期報告其評估ozekibart (INBRX-109)聯合FOLFIRI用於局部晚期或轉移性、不可切除結直腸癌(CRC)患者的1/2期研究的積極更新中期數據。Inhibrx亦宣布已於4月向FDA提交ozekibart用於常規軟骨肉瘤的生物製品許可申請。

根據通過公司全資子公司奕安濟世簽署的許可協議，創勝醫藥擁有在內地、香港、澳門及台灣地區開發及商業化ozekibart (INBRX-109)的獨家權利。鑑於ozekibart的該等積極進展，創勝醫藥正積極評估其於大中華區的計劃。(jl/da)(HK stocks quote is delayed for at least 15 mins.) (Real-time Streaming US Stocks Quote; Except All OTC quotes are at least 15 minutes delayed.)

Switch to Auto-Translated Version
AASTOCKS新聞
Copyright(C) AASTOCKS.com Limited 2000. All rights reserved.
Disclaimer: AASTOCKS.com Ltd, HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the Information provided but do not guarantee its accuracy or reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.